A Parents Guide to Drugs 2014
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Substance Abuse: the Pharmacy Educator’S Role in Prevention and Recovery
Substance Abuse: The Pharmacy Educator’s Role in Prevention and Recovery Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease i Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease1,2 BACKGROUND OF THE CURRICULUM DEVELOPMENT PROJECT In 1988, the AACP Special Interest Group (SIG) on Pharmacy Student and Faculty Impairment (renamed Substance Abuse Education and Assistance) undertook the development of curricular guidelines for colleges/schools of pharmacy to facilitate the growth of educational opportunities for student pharmacists. These Curricular Guidelines for Pharmacy Education: Substance Abuse and Addictive Disease were published in 1991 (AJPE. 55:311-16. Winter 1991.) One of the charges of the Special Committee on Substance Abuse and Pharmacy Education was to review and revise the 1991 curricular guidelines. Overall, the didactic and experiential components in the suggested curriculum should prepare the student pharmacist to competently problem-solve issues concerning alcohol and other drug abuse and addictive diseases affecting patients, families, colleagues, themselves, and society. The guidelines provide ten educational goals, while describing four major content areas including: psychosocial aspects of alcohol and other drug use; pharmacology and toxicology of abused substances; identification, intervention, and treatment of people with addictive diseases; and legal/ethical issues. The required curriculum suggested by these guidelines addresses the 1 These guidelines were revised by the AACP Special Committee on Substance Abuse and Pharmacy Education. Members drafting the revised guidelines were Edward M. DeSimone (Creighton University), Julie C. Kissack (Harding University), David M. Scott (North Dakota State University), and Brandon J. Patterson (University of Iowa). Other Committee members were Paul W. Jungnickel, Chair (Auburn University), Lisa A. -
Programme & Abstracts
The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday. -
From Sacred Plants to Psychotherapy
From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine). -
Ecstasy Or Molly, Is a Synthetic Psychoactive Drug
DRUG ENFORCEMENT ADMINISTRATION THE FACTS ABOUT MDMA Ecstasy &Molly DEA PHOTO What is it? MDMA, (3,4-methylenedioxy- methamphetamine), known as Ecstasy or Molly, is a synthetic psychoactive drug. Ecstasy is the pill form of MDMA. Molly is the slang for “molecular” that refers to the powder or crystal form of MDMA. Molly is often mixed with other drugs and substances and is not pure MDMA or safe to use. How is it used? MDMA or Ecstasy is taken orally in pill or tablet form. These pills can be in different colors with images on them. Molly is taken in a gel capsule or snorted. What does MDMA do to the body and mind? • As a stimulant drug, it increases heart rate and blood pressure. Users may experience muscle tension, involuntary teeth clenching, nausea, blurred vision, faintness, chills, or sweating • It produces feelings of increased energy, euphoria, emotional warmth, empathy, and distortions in sensory and time perception. • Feelings of sadness, anxiety, depression and memory difficulties are other effects. • It can seriously deplete serotonin levels in the brain, causing confusion and sleep problems. Did you know? • DEA has labeled MDMA as a Schedule I drug, meaning its abuse potential is high and it has no approved medical use. It is illegal in the U.S. • In high doses, MDMA can affect the body’s ability to regulate temperature, which can lead to serious health complications and possible death. • Teens are using less MDMA. Teens decreased their past year use of MDMA from 1.9% in 2010 to 1.2% of teens using 2012. -
Psychoactive Substances and Transpersonal States
TRANSPERSONAL PSYCHOLOGY RESEARCH REVIEW: PSYCHOACTIVE SUBSTANCES AND TRANSPERSONAL STATES David Lukoff San Francisco, California Robert Zanger Los Angeles, California Francis Lu San Francisco, California This "Research Review" covers recent trends in researching psychoactive substances and trans personal states of conscious ness during the past ten years. In keeping with the stated goals of this section of the Journal to promote research in transpersonal psychology, the focus is on the methods and trends designs which are being employed in investigations rather than during the findings on this topic. However, some recently published the books and monographs provide good summaries of the recent last findings relevant to understanding psychoactive substances ten (Cohen & Krippner, 1985b; Dobkin de Rios, 1984;Dobkin de years Rios & Winkelman, 1989b; Ratsch, 1990; Reidlinger, 1990). Because researching psychoactive substances is most broadly a cross-disciplinary venture, only a small portion of the research reviewed below was conducted by persons who consider The authors wish to acknowledge the assistance of Bruce Flath, head librarian at the California Institute of Integral Studies, San Francisco in conducting the computer bibliographic searches used in preparation of this article. The authors also wish to thank Marlene Dobkin de Rios, Stanley Krippner, Christel Lukoff, Dennis McKenna, Terence McKenna, Ralph Metzner, Donald Rothberg and Ilene Serlin for their valuable comments on earlier drafts of this article. Copyright © 1990 Transpersonal Institute The Journal of Transpersonal Psychology. 1990, Vol. 22, No.2 107 themselves transpersonal psychologists. As Vaughan (1984) has noted, "The transpersonal perspective is a meta-perspec tive, an attempt to learn from all different disciplines . emerging from the needed integration of ancient wisdom and modern science. -
Psilocybin Mushrooms Fact Sheet
Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses. -
PSYCHEDELIC DRUGS (P.L) 1. Terminology “Hallucinogens
PSYCHEDELIC DRUGS (p.l) 1. Terminology “hallucinogens” – induce hallucinations, although sensory distortions are more common “psychotomimetics” – to minic psychotic states, although truly most drugs in this class do not do so “phantasticums”or “psychedelics” – alter sensory perception (Julien uses “psychedelics”) alterations in perception, cognition, and mood, in presence of otherwise clear ability to sense” may increase sensory awareness, increase clarity, decrease control over what is sensed/experienced “self-A” may feel a passive observer of what “self-B” is experiencing often accompanied by a sense of profound meaningfulness, of divine or cosmic importance (limbic system?) these drugs can be classified by what NT they mimic: anti-ACh, agonists for NE, 5HT, or glutamate (See p. 332, Table 12.l in Julien, 9th Ed.) 2. The Anti-ACh Psychedelics e.g. scopolamine (classified as an ACh blocker) high affinity, no efficacy plant product: Belladonna or “deadly nightshade” (Atropa belladonna) Datura stramonium (jimson weed, stinkweed) Mandragora officinarum (mandrake plant) pupillary dilation (2nd to atropine) PSYCHEDELIC DRUGS (p.2) 2. Anti-ACh Psychedelics (cont.) pharmacological effects: e.g. scopolamine (Donnatal) clinically used to tx motion sickness, relax smooth muscles (gastric cramping), mild sedation/anesthetic effect PNS effects --- dry mouth relaxation of smooth muscles decreased sweating increased body temperature blurred vision dry skin pupillary dilation tachycardia, increased BP CNS effects --- drowsiness, mild euphoria profound amnesia fatigue decreased attention, focus delirium, mental confusion decreased REM sleep no increase in sensory awareness as dose increases --- restlessness, excitement, hallucinations, euphoria, disorientation at toxic dose levels --- “psychotic delirium”, confusion, stupor, coma, respiratory depression so drug is really an intoxicant, amnestic, and deliriant 3. -
10 Facts About MDMA
10 Facts About MDMA August 2015 1. What is MDMA? and a desire to intensify these feelings by dancing, talking and touching. MDMA, often referred to as “ecstasy” or “molly”, is short for 3,4 methylenedioxymethamphetamine, a A typical dose of 80 - 125 mg lasts three to six hours. psychoactive drug derived from safrole oil. MDMA Some people experience nausea at the outset, but produces effects that resemble both stimulants and after about 45 minutes, report feelings of relaxation psychedelics, as well as its signature effect: a feeling and clarity. MDMA also causes dilation of the pupils of connectedness. It impacts brain function primarily and, often, sensitivity to light, as well as possible jaw- releasing the neurotransmitter serotonin, and also clenching, tooth-grinding, muscle tension, faintness, temporarily inhibits its reuptake. MDMA is usually and chills or sweating. taken orally, whether in pressed pill form, powder or crystal; or sometimes snorted. After the drug wears off, the theory from preclinical studies is that brain levels of serotonin (a chemical MDMA was originally synthesized in 1912 by the drug responsible for maintaining mood balance) are company Merck.1 However, its psychoactive effects depleted, which can lead in some cases to sadness, weren’t widely discovered until 1976 when Alexander anxiety, depression and sleep problems.4 If they occur, Shulgin developed a new synthesis method, tested the these symptoms arise in the several days that follow. drug on himself, and shared it with a few friendly Generally, they abate within a week, though frequency psychotherapists.2 Because of the drug’s effects of of use and higher doses can slow or stop this increasing empathy and reducing fear, it started to be process.5 used in psychotherapy practices in the 1970s and early 80s, as well as recreationally. -
CLINICAL STUDY PROTOCOL Psilocybin-Assisted Psychotherapy
CLINICAL STUDY PROTOCOL Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma. Version: Final IND: [79,321] SPONSOR Multidisciplinary Association for Psychedelic PRINCIPAL INVESTIGATOR Sameet Kumar Ph.D. MEDICAL MONITOR Michael C. Mithoefer MD. STUDY PERSONNEL XXXXXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXXXXXX STUDY MONITOR [CRA] Valerie Mojeiko IRB Study Site IRB Sponsor Signatory Rick Doblin Ph.D. Study Period 2008 For trial related emergencies please contact: Dr. Michael Mithoefer MAPS: S Kumar PI Clinical Study Protocol PCA1 Final December 1, 2007 Confidential Page 2 of 83 Table of Contents Introduction......................................................................................................................... 4 Background..................................................................................................................... 4 Disease History and Related Research ........................................................................... 5 Rationale ......................................................................................................................... 7 Summary......................................................................................................................... 7 Ethics................................................................................................................................... 8 Informed Consent of Subject .......................................................................................... 9 Recruitment and Screening............................................................................................ -
Commonly Used Drugs
Commonly Used Drugs Many drugs can alter a person’s thinking and judgment, and can lead to health risks, including addiction, drugged driving, infectious disease, and adverse effects on pregnancy. Information on commonly used drugs with the potential for misuse or addiction can be found here. For information about treatment options for substance use disorders, see NIDA’s Treatment pages. For drug use trends, see our Trends and Statistics page. For the most up-to-date slang terms, please see Slang Terms and Code Words: A Reference for Law Enforcement Personnel (DEA, PDF, 1MB). The following drugs are included in this resource: ➢ Alcohol ➢ Methamphetamine ➢ Ayahuasca ➢ Over-the-Counter Medicines--Dextromethorphan ➢ Central Nervous System Depressants (DXM) ➢ Cocaine ➢ Over-the-Counter Medicines--Loperamide ➢ DMT ➢ PCP ➢ GHB ➢ Prescription Opioids ➢ Hallucinogens ➢ Prescription Stimulants ➢ Heroin ➢ Psilocybin ➢ Inhalants ➢ Rohypnol® (Flunitrazepam) ➢ Ketamine ➢ Salvia ➢ Khat ➢ Steroids (Anabolic) ➢ Kratom ➢ Synthetic Cannabinoids ➢ LSD ➢ Synthetic Cathinones ("Bath Salts") ➢ Marijuana (Cannabis) ➢ Tobacco/Nicotine ➢ MDMA (Ecstasy/Molly) ➢ Mescaline (Peyote) **Drugs are classified into five distinct categories or schedules “depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential.” More information and the most up-to-date scheduling information can be found on the Drug Enforcement Administration’s website. June 2020 Alcohol People drink to socialize, celebrate, and relax. Alcohol often has a strong effect on people—and throughout history, people have struggled to understand and manage alcohol’s power. Why does alcohol cause people to act and feel differently? How much is too much? Why do some people become addicted while others do not? The National Institute on Alcohol Abuse and Alcoholism is researching the answers to these and many other questions about alcohol. -
Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: Achildpsychiatrist’S Perspective
Neurotherapeutics DOI 10.1007/s13311-017-0531-1 REVIEW Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: AChildPsychiatrist’s Perspective Ben Sessa1 # The Author(s) 2017. This article is an open access publication Abstract Since the late 1980s the psychoactive drug 3,4- pharmacotherapies and psychotherapies for treating complex methylenedioxymethamphetamine (MDMA) has had a well- post-traumatic stress disorder arising from child abuse. known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as Key Words MDMA . PTSD . Psychotherapy . Trauma . a therapeutic agent and that in recent years an increasing Psychedelics . addictions amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmaco- logical properties that translate well to its proposed agent to Introduction: From Child Abuse and Mental assist trauma-focused psychotherapy. Psychological trauma— Disorder to Addictions especially that which arises early in life from child abuse— and 3,4-Methylenedioxymethamphetamine underpins many chronic adult mental disorders, including ad- dictions. Several studies of recent years have investigated the I am a child and adolescent psychiatrist, who also works with potential role of MDMA-assisted psychotherapy as a treat- adults with addictions. My adult patients in their 20s, 30s, and ment for post-traumatic stress disorder, with ongoing plans beyond with unremitting depression, anxiety, post-traumatic to see MDMA therapy licensed and approved within the next stress disorder (PTSD), and substance abuse are sadly the 5 years. Issues of safety and controversy frequently surround same type of patients that I also care for as abused children. -
The Use of Psychedelic Drugs in the Treatment of Problematic Drug and Alcohol Use
Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use Short Title: Illicit drugs in the treatment of addiction Celia Morgan 1,3, Amy McAndrew1, Tobias Stevens1, David Nutt2, Will Lawn1,3 1. Psychopharmacology and Addiction Research Centre, University of Exeter, UK 2. Centre for Neuropsychopharmacology, Imperial College London, UK 3. Clinical Psychopharmacology Unit, University College London, UK Address Corrrespondence to: Celia Morgan Psychopharmacology and Addiction Research Centre Washington Singer Laboratory University of Exeter Perry Road, Exeter Devon UK EX4 4QG Key words: addiction, psychedelics, ketamine, ibogaine, ayahuasca, LSD , psilocybin, neurogenesis, 1 Highlights: Psilocybin may reduce alcohol and tobacco use in addicted samples. Ibogaine and ayahuasca have shown promise in the treatment of various addictions through observational studies. Ketamine has been used to treat alcohol dependence and reduces cocaine self- administration in the human laboratory. Randomised controlled trials are greatly needed to further test the efficacy of all of these compounds. Psychedelic drugs may have their therapeutic qualities due to anti-depressant effects, stimulating neuroplasticity and long-term psychological changes. 2 Abstract Psychedelic drugs have been used as treatments in indigenous cultures for thousands of years. Yet, due to their legal status, there has been limited scientific research into the therapeutic potential of these compounds for psychiatric disorders. In the absence of other effective treatments however, researchers have begun again to systematically investigate such compounds and there is now evidence pointing to the use of psychedelic drugs in the treatment of addiction. In this review we focus on human evidence for the effectiveness of preparations used by indigenous cultures in the Amazon (ayahausca) and Africa (ibogaine) and worldwide (psilocybin), and more recently synthetised drugs such as the serotonergic hallucinogen LSD and the dissociative anaesthetic ketamine.